Systemic Chemotherapy with and without Anti-EGFR Antibody in the First-line Treatment of Metastatic Colorectal Cancer

Li-da Wang¹, Cuai Ren², Weide Zhang³, Xiao-yan Ma⁴ and Zhi-xin Sheng²*

¹Department of E.N.T. Weifang People’s Hospital, Weifang, The People’s Republic of China
²Department of Hematology, Weifang People’s Hospital, Weifang, The People’s Republic of China
³The Postgraduate of Weifang Medical University, The People’s Republic of China
⁴ICU, Affiliated Weifang People’s Hospital of Weifang Medical University, The People’s Republic of China

Abstract

To define whether or not the addition of anti-EGFR monoclonal antibodies to standard chemotherapy, compared with chemotherapy alone, can improve Overall Survival (OS) and Progression-Free Survival (PFS) in the patients with Metastatic Colorectal Cancer (mCRC), and evaluate the influence of KRAS mutant status on the efficacy of anti-EGFR antibodies in the first-line setting. Medline, Embase and the Cochrane controlled trials register were searched. Six trials were identified, covering a total of 4,988 subjects. A significant benefit of anti-EGFR based regimen as first-line treatment was found for OS (HR, 0.89, 95% CI: [0.80, 0.99]; P=0.04) and for PFS (HR, 0.85 [0.77, 0.94]; P=0.002) among the overall population. The PFS benefit are probably limited to KRAS wild-type patients (HR, 0.83 [0.69, 0.99]; P=0.03). No significant benefit was found among KRAS-positive patients: The summary HRs was 1.13 [0.91, 1.38] (P=0.26) for PFS, 1.06 [0.94, 1.19] (P=0.34) for OS, respectively. In conclusion, our data demonstrated that the addition of anti-EFGR antibodies to chemotherapy for mCRC improved overall and progression-free survival for the overall population in the first-line setting. And the benefit from anti-EGFR antibodies as first-line treatment seems to be limited to patients with KRAS wild-type tumors with respect to PFS.

Keywords: Colorectal cancer; Anti-EGFR monoclonal body; First-line therapy

Introduction

Standard systemic chemotherapy has improved the outcome of patients with advanced colorectal rectal cancer (CRC) [1-3], but the disease is still incurable in the majority of patients. Recently, the development of anti-Epidermal Growth Factor Receptor (EGFR) antibody, cetuximab or panitumumab, have provided a new treatment option [4]. Several metastatic colorectal cancer (mCRC) trials have demonstrated the efficacy of anti-EGFR antibodies, as monotherapy [5,6] or combined with chemotherapy [7,8], after the failure of previous chemotherapy treatment. In the first-line setting, building on promising results from phase I/II trial [9], Several phase III studies examining the activity of cetuximab or panitumumab have provided encouraging results [10,11]. First-line treatment with anti-EGFR antibodies has produced a pronounced shift in the treatment framework for patients with mCRC. The substantial clinical benefits of first-line anti-EGFR antibodies treatment for patients with mCRC in the subsequent trials raise this question about whether first-line treatment with the combination of anti-EGFR antibodies and chemotherapy is more beneficial than systemic chemotherapy alone for the overall population or for the molecularly defined subgroup. With variable results, we did this pooled-analysis to address those issues at least in part. In some trials [10-12], the definition of molecular characteristic of EFGR wild-type mutant has been documented to enable the selection of patients most likely to benefit from particular treatments. We also undertook a subgroup analysis to investigate whether tumor KRAS mutation status was predictive of a favorable outcome to anti-EFGR antibodies plus systemic chemotherapy.

Methods

Literature search strategy

Medline, Embase and the Cochrane controlled trials register were searched for randomized control trials (RCTs) using the medical subject headings of colorectal cancer combining with each of the following terms of phrases: anti-EGFR targeted therapy, anti-EGFR monoclonal antibody, cetuximab, panitumumab. Reference lists from studies selected for this review were also hand-searched.

Selection of studies

Studies were eligible for inclusion in the meta-analysis if they met all the following criteria: (1) they were published up to June 2011 and written in English, (2) they dealt only with patients with mCRC or Advanced Colorectal Cancer (ACC) in the first-line setting, (3) they provided data on PFS and OS regardless of immunohistochemical evidence of EGFR expression, (5) Intervention: anti-EGFR antibody plus the same chemotherapy regimen, (6) Control: systemic chemotherapy alone. Multiple reports of a single study were considered as one publication, and only the most recent and complete data were examined. All potentially relevant articles were reviewed by two independent investigators (L.D.W and Z.X.S.).

Outcome measures

We considered the treatment effects (anti-EGFR treatment group vs. control) on OS and PFS between the groups for the overall population as the primary outcome, for the subgroup defined by KRAS mutation status as secondary outcome. PFS was measured...
from the date of enrollment, randomization or treatment start until disease progression, relapse, or death. OS was measured from the date of enrollment, randomization or treatment start until death from any cause.

Quality assessment

Two reviewers (L.D.W and Z.X.S) independently assessed the quality of selected studies using the following criteria: (1) generation of allocation concealment, (2) description of drop-outs, (3) masking of randomization, intervention, outcome assessment, and (4) intention-to-treat (ITT) analyses. Each criterion was rated as yes, no or unclear.

Statistical analysis

All survival data (PFS, OS), were pooled and reported as Hazard Ratio (HR) with inverse variance method. For each included RCT, for the purpose of analysis, we calculated the log rank of HR, and its standard error to perform this meta-analysis. A value less than 1.0 means, the anti-EGFR effect is more favorable in patients with mCRC compared with chemotherapy alone, whereas a value greater than 1.0 means the opposite. We extracted survival data on the treatment effect for overall population, KRAS-mutant and wild-type subpopulation respectively. When not available from the trial reports, they were estimated with the methods proposed by Parmar et al. [13] and described elsewhere [14]. A random effects model was used for all the analyses, which incorporates the variability of results among trials and provided a more conservative estimate of an effect size by producing greater Confidence Intervals (CIs) [15].

We tested for heterogeneity of between-study and between-subgroup with the Cochrane χ2 test (considered significant at the 0.10 level) and quantified its extent with the I² statistic. If significant heterogeneity existed, it would be appropriate to pool the data using random-effects model, but not fixed-effect model.

Begg’s funnel plots [16] and Egger’s test [17] were used to detect possible publication bias, and meta-regression analysis was employed to detect the source of heterogeneity in the survival analysis (considered significant at the 0.15 level). All meta-analyses were completed using Review Manager (version 5.1, The Cochrane Collaboration, Oxford, England) and Stata ver.10 software (College Station, TX, USA).

Table 1: Characteristics of included studies.

| Study or Subgroup | log(Hazard Ratio) | SE | Weight | Hazard Ratio IV, Random, 95% CI | Hazard Ratio IV, Random, 95% CI |
|-------------------|------------------|----|--------|---------------------------------|---------------------------------|
| 1.1.1 Overall survival in overall population | | | | | |
| Borner 2008       | -0.424           | 0.3162 | 3.1% | 0.65 [0.35, 1.22]              |                                  |
| Cutsem 2011       | -0.1301          | 0.0641 | 54.4% | 0.88 [0.77, 1.00]              |                                  |
| Douillard 2010    | -0.1863          | 0.1072 | 26.0% | 0.83 [0.67, 1.02]              |                                  |
| Tveit 2011        | 0.0583           | 0.1241 | 18.5% | 1.06 [0.83, 1.35]              |                                  |
| Subtotal (95% CI) |                  |     | 100.0% | 0.89 [0.80, 0.99]              |                                  |
| Heterogeneity: Tau² = 0.00; Chi² = 3.40, df = 3 (P = 0.33); I² = 12% | | | | |
| Test for overall effect: Z = 2.09 (P = 0.04) | | | | |

1.1.2 Progression-free survival in overall population

| Subgroup | log(Hazard Ratio) | SE | Weight | Hazard Ratio IV, Random, 95% CI | Hazard Ratio IV, Random, 95% CI |
|----------|------------------|----|--------|---------------------------------|---------------------------------|
| Borner 2008 | -0.0715       | 0.142 | 12.7% | 0.93 [0.70, 1.23]              |                                  |
| Cutsem 2011 | -0.1613       | 0.0577 | 0.8% | 0.85 [0.27, 2.64]              |                                  |
| Douillard 2010 | -0.2231     | 0.0982 | 26.6% | 0.80 [0.66, 0.97]              |                                  |
| Tveit 2011    | -0.1165       | 0.1104 | 21.0% | 0.89 [0.72, 1.11]              |                                  |
| Subtotal (95% CI) |                  |     | 100.0% | 0.85 [0.77, 0.94]              |                                  |
| Heterogeneity: Tau² = 0.00; Chi² = 0.95, df = 4 (P = 0.92); I² = 0% | | | | |
| Test for overall effect: Z = 3.10 (P = 0.002) | | | | |

Figure 1: Meta-analysis of the treatment effects (anti-EGFR antibody vs control) on overall survival (top) and progression-free survival (below) with anti-EGFR antibody for the overall population, HR, hazard ratio; CI, 95% confidence interval. Random, random-effects model.
Statistical significance was defined as a P value of less than 0.05 for all tests except those for heterogeneity and regression.

Results

A comprehensive search of Medline, Embase, and the Cochrane controlled trials register and the Science Citation Index yielded 659 articles, of which 6 studies met the predetermined inclusion criteria. The six trials enrolled a total of 4,988 patients. Their characteristics are described in Table 1. Four included RCTs reported final analyses. None was double-blinded. All studies reported intention-to-treat (ITT) analyses and description of drop-outs except for the two [18,19]. We did not find any graphical or statistical evidence of publication bias for all outcomes.

As shown in Figure 1, a significant benefit of anti-EGFR based treatment as first-line treatment was found for overall survival (OS) (HR, 0.89, 95% CI: [0.80, 0.99]; P=0.04) and for progression-free survival (PFS) (HR, 0.85 [0.77, 0.94]; P=0.002) respectively, among the overall population.

As shown in Figure 2, top, the random-effects summary relative HR comparing the treatment effect on PFS between the addition of anti-EGFR antibodies to chemotherapy and systemic chemotherapy alone was 0.83 [0.69, 0.99] (P=0.03), indicating that benefits from anti-EGFR regimens are probably limited to KRAS wild-type patients. However, the survival benefit for the addition of anti-EGFR antibodies to chemotherapy was not detected in Figure 3 (HR, 0.92 [0.78, 1.08], P=0.30). As shown in Figure 2 & 3, pooling 4 analyses of randomized trials of anti-EGFR antibodies plus chemotherapy versus systemic chemotherapy alone was 0.83 [0.69, 0.99] (P=0.26) for PFS, 1.06 [0.94, 1.19] (P=0.34) for OS, respectively.

| Study or Subgroup | log[Hazard Ratio] | SE | Weight | Hazard Ratio IV, Random, 95% CI | Hazard Ratio IV, Random, 95% CI |
|-------------------|------------------|----|--------|-----------------|-----------------|
| **1.2 KRAS wild-type subpopulation** | | | | | |
| Bokemeyer 2009 | -0.5621 | 0.2371 | 10.1% | 0.57 [0.36, 0.91] |  |
| Cutsem 2011 | -0.3624 | 0.1124 | 22.1% | 0.70 [0.56, 0.87] |  |
| Douillard 2010 | -0.2231 | 0.0962 | 24.1% | 0.80 [0.66, 0.97] |  |
| Maughan 2011 | -0.0468 | 0.0795 | 26.8% | 0.90 [0.82, 1.12] |  |
| Tveit 2011 | -0.0677 | 0.1549 | 16.9% | 1.07 [0.79, 1.45] |  |
| **Subtotal (95% CI)** | 100.0% | 0.83 [0.69, 0.99] |  |
| **Heterogeneity:** Tau² = 0.01; Chi² = 2.47, df = 3 (P = 0.48); I² = 63% | | | | |
| Test for overall effect: Z = 1.04 (P = 0.30) | | | | |
| **1.3.1 KRAS mutant subpopulation** | | | | | |
| Bokemeyer 2009 | 0.0643 | 0.2618 | 11.2% | 1.03 [1.10, 3.06] |  |
| Cutsem 2011 | 0.1579 | 0.1414 | 20.9% | 1.17 [0.89, 1.55] |  |
| Douillard 2010 | 0.2549 | 0.1131 | 24.1% | 1.29 [1.03, 1.61] |  |
| Maughan 2011 | 0.0583 | 0.0868 | 27.1% | 1.06 [0.90, 1.25] |  |
| Tveit 2011 | -0.3425 | 0.1844 | 16.7% | 0.71 [0.49, 1.02] |  |
| **Subtotal (95% CI)** | 100.0% | 1.13 [0.91, 1.39] |  |
| **Heterogeneity:** Tau² = 0.04; Chi² = 11.70, df = 4 (P = 0.02; I² = 66%) | | | | |
| Test for overall effect: Z = 1.12 (P = 0.26) | | | | |

Figure 2: Meta-analysis of the treatment effects (anti-EGFR antibody vs control) on progression-free survival for the subgroup defined by KRAS mutant status, HR, hazard ratio; CI, 95% confidence interval. Random, random-effects model.

| Study or Subgroup | log[Hazard Ratio] | SE | Weight | Hazard Ratio IV, Random, 95% CI | Hazard Ratio IV, Random, 95% CI |
|-------------------|------------------|----|--------|-----------------|-----------------|
| **1.3.2 KRAS mutant subpopulation** | | | | | |
| Cutsem 2011 | 0.0344 | 0.1101 | 28.7% | 1.03 [0.83, 1.28] |  |
| Douillard 2010 | 0.2151 | 0.1202 | 24.1% | 1.24 [0.98, 1.57] |  |
| Maughan 2011 | -0.0032 | 0.0938 | 39.6% | 0.98 [0.82, 1.18] |  |
| Tveit 2011 | 0.0296 | 0.2135 | 17.6% | 1.03 [0.88, 1.17] |  |
| **Subtotal (95% CI)** | 100.0% | 1.06 [0.94, 1.19] |  |
| **Heterogeneity:** Tau² = 0.01; Chi² = 2.47, df = 3 (P = 0.48); I² = 0% | | | | |
| Test for overall effect: Z = 0.95 (P = 0.34) | | | | |

Figure 3: Meta-analysis of the treatment effects (anti-EGFR antibody vs control) on overall survival for the subgroup defined by KRAS mutant status, HR, hazard ratio; CI, 95% confidence interval. Random, random-effects model.
The overall population.

Analysis and from 0.84 [0.76, 0.94] to 0.88 [0.78, 0.98] for PFS analysis yielded HRs ranging from 0.86 [0.77, 0.95] to 0.91 [0.77, 1.08] for OS when any single study was excluded. This was important because the imbalance administration of anti-EGFR antibodies in the post-study phase could explain the absence of survival benefit at least in part.

In the meta-regression of all interesting variables (the type of anti-EGFR antibody (cetuximab vs. panitumumab) and concomitant chemotherapy (platinum vs. non-platinum based chemotherapy, study type (phase II vs. phase III) on the HRs, none of the individual study characteristics was significantly related to the predicted OR. Given the small number of studies included in the meta-regression, however, this interpretation must be tentative.

Several other limitations should be considered when interpreting our findings: Firstly, we had no access to primary data and only used abstracted data, while an individual patient data based meta-analysis would have provided a more robust estimate of the efficacy of the addition of anti-EGFR antibody to chemotherapy in the first-line setting [21]. Secondly, the effect of heterogeneity usually needs to be taken into account in meta-analysis. Last, relatively little information on the methods and analyses of this unpublished study [19] made detailed quality assessments challenging.

**Conclusion**

Our data demonstrated that the addition of anti-EGFR antibodies to chemotherapy for mCRC improved overall and progression-free survival for the overall population of unselected patients in the first-line setting. And the benefit from anti-EGFR antibodies as first-line treatment seems to be limited to patients with KRAS wild-type tumors with respect to PFS in the first-line setting. And we did not detect any benefit of anti-EGFR antibodies for overall and progression-free survival in patients with KRAS mutant tumors. Unexpected, the survival benefit of anti-EGFR antibodies did not emerge in this pooled-analysis. The imbalance administration of anti-EGFR antibodies in the post-study phase could explain the absence of survival benefit at least in part.

In the meta-regression of all interesting variables (the type of anti-EGFR antibody (cetuximab vs. panitumumab) and concomitant chemotherapy (platinum vs. non-platinum based chemotherapy, study type (phase II vs. phase III) on the HRs, none of the individual study characteristics was significantly related to the predicted OR. Given the small number of studies included in the meta-regression, however, this interpretation must be tentative.

Several other limitations should be considered when interpreting our findings: Firstly, we had no access to primary data and only used abstracted data, while an individual patient data based meta-analysis would have provided a more robust estimate of the efficacy of the addition of anti-EGFR antibody to chemotherapy in the first-line setting [21]. Secondly, the effect of heterogeneity usually needs to be taken into account in meta-analysis. Last, relatively little information on the methods and analyses of this unpublished study [19] made detailed quality assessments challenging.

**Conclusion**

Our data demonstrated that the addition of anti-EGFR antibodies to chemotherapy for mCRC improved overall and progression-free survival for the overall population of unselected patients in the first-line setting. And the benefit from anti-EGFR antibodies as first-line treatment seems to be limited to patients with KRAS wild-type tumors with respect to PFS.

**References**

1. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, et al. (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343: 905-914.
2. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, et al. (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22: 23-30.
3. Van Cutsem E, Geboes K (2007) The multidisciplinary management of gastrointestinal cancer. The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer. Best Pract Res Clin Gastroenterol 21: 1089-1108.
4. Kang X, Patel D, Ng S, Melchior M, Ludwig D, et al. (2007) High affinity Fc
receptor binding and potent induction of antibody-dependent cellular cytotoxicity (ADCC) in vitro by anti-epidermal growth factor receptor antibody cetuximab. J Clin Oncol 25: 18a.

5. Van Cutsem E, Peeters M, Siena S, Humbel Y, Hendriks A, et al. (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25: 1658-1684.

6. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, et al. (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357: 2040-2048.

7. Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, et al. (2008) EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26: 2311-2319.

8. Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, et al. (2010) Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28: 4706-4713.

9. Rautou JL, Van Laethem JL, Peeters M, Brezault C, Hussein F, et al. (2009) Cetuximab in combination with irinotecan/5-fluorouracil/leucovorin (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase III study. BMC Cancer 9:112.

10. Van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP, et al. (2011) Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29: 2011-2019.

11. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, et al. (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28: 4697-4705.

12. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, et al. (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27: 663-671.

13. Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17: 2815-2834.

14. Tierney JF, Stewart LA, Gherse D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16.

15. Berlin JA, Laird NM, Sacks HS, Chalmers TC (1989) A comparison of statistical methods for combining event rates from clinical trials. Stat Med B: 141-151.

16. Beg B, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088-1101.

17. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.

18. Borner M, Koeberle D, Von Moos R, Saletti P, Rauch D, et al. (2008) Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK. Ann Oncol 19: 1288-1292.

19. Tveit K, Guren T, Gilmelius B, Pfeiffer P, Sorebo H, et al. (2011) Randomized phase III study of 5-fluorouracil/folinic/oxaliplatin given continuously or intermittently with or without cetuximab, as first-line treatment of metastatic colorectal cancer: The NORDIC VII study (NCT00145314), by the Nordic Colorectal Cancer Biomodulation Group. J Clin Oncol 29.

20. Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A (2009) Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 101:1308-1324.

21. Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, et al. (2011) Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 377: 2103-2114.